Protonix settlement unlikely to eclipse Sun's business plans
This article was originally published in Scrip
Sun Pharmaceutical Industries is unlikely to scale down its growth projections for 2014 or rein in plans to expand via acquisitions as a result of the $550 million settlement over the patent dispute concerning its generic version of Pfizer's gastroesophageal reflux disease treatment, Protonix (pantoprazole).
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.